NovoCure Limited Outlook Following Pre-Announced Q4 Revenue Miss
<p>Analyst at Oppenheimer spoke with <a href='https://financialmodelingprep.com/financial-summary/NVCR'>NovoCure Limited (NASDAQ:NVCR)</a> management following the company’s pre-announced Q4 revenue, which came in at $133.2 million, missing the consensus estimate of $152.5 million.</p>
<p>The key takeaways of the meeting include the following:</p>
<p>(1)	While the miss was across geographies, EMEA accounted for the largest miss due in part to a $4 million impact from new contracting in Germany.</p>
<p>(2)	2022 active user growth of 2-5% implies a downward revision to Oppenheimer’s revenue estimates.</p>
<p>(3)	limited disruption to clinical trials from COVID. </p>
<p>The analysts lowered their GBM estimates across geographies for 2022 and beyond, now expecting total 2022 sales to be $561.5 million, compared to their previous $619.9 million estimate. While the analysts maintained their Perform rating, they view risk/reward outlook as improving and are focused on Metis study as an attractive path to the intermediate-term upside.</p>

NASDAQ:NVCR